Notable Thursday Option Activity: CRWD, GS, QGEN

Goldman Sachs (GS) saw options volume of 32,900 contracts (~3.3 million underlying shares), about 134.4% of its one‑month average daily volume (2.4M shares), led by 1,376 contracts in the $850 put expiring Feb 6, 2026 (≈137,600 shares). Qiagen NV (QGEN) registered 43,409 option contracts (~4.3M underlying shares), roughly 134.3% of its one‑month average (3.2M shares), with heavy activity in the $55 call expiring May 15, 2026 (21,757 contracts, ≈2.2M shares). The elevated activity in specific strikes and expirations signals concentrated positioning or hedging that could drive near‑term price moves and volatility in the two names.

Analysis

Market structure: The outsized options flows (GS: 1,376 puts = 137,600 shares; QGEN: 21,757 calls = ~2.2M shares) imply institutional directional or hedging activity that will force dealer delta-hedging and amplify stock moves into the Feb 6, 2026 (GS) and May 15, 2026 (QGEN) expiries. Direct beneficiaries are call buyers in QGEN and put buyers in GS; dealers and liquidity providers collect premium but face gamma risk. Cross-asset impact: amplified equity moves can tighten corporate credit spreads for banks (GS stress) and push defensive FX flows (USD safe-haven) if selling intensifies.

Risk assessment: Tail risks include a large block being a synthetic hedge for M&A or a hedge fund forced liquidation—both can cause >10-20% intraday swings pre-expiry; regulatory (bank capital/diagnostics approval) or liquidity shocks could cascade into bonds and ETFs. Immediate (days): gamma-induced volatility; short-term (weeks–months): position roll/expiry dynamics; long-term: fundamentals reassert post-expiry. Hidden dependency: these prints may be sell-to-open from structured-product issuance, not pure directional buys—interpret OI and block trade data.

Trade implications: Favor asymmetric, capped-risk option structures. Tactical: buy QGEN May 15, 2026 55/60 call spread (target 2x, max loss = premium, size 1–2% NAV) within 3 trading days to ride flow-driven momentum and potential M&A/clinical catalysts. Hedge/contrarian: allocate 0.5–1% NAV to a GS Feb 6, 2026 put spread (buy 850/700 or nearest liquid strikes) as downside insurance; consider pair trade long QGEN call spread / short XLF 1% to neutralize market beta.

Contrarian angles: The consensus that large call volume = bullish may be wrong—flows could be dealers selling calls or structured-product sellers creating synthetic long stock; if IV spikes >40% above today, premium is likely overpriced and mean-reversion trade (calendar or iron condor) becomes attractive. Historical parallels: 2018/2020 gamma squeezes show rapid reversals after hedges are unwound. Monitor block-trade prints, OI changes and SEC/insider filings (next 30–60 days) to avoid being trapped by flow-driven, non-fundamental moves.

Key Decisions for Investors

• Establish a 1.5% NAV position: buy QGEN May 15, 2026 55/60 call spread (debit), enter within 3 trading days, target 100% gain, hard stop at 50% premium loss or close if QGEN moves up >20% intraday.
• Allocate 0.75–1.0% NAV to downside protection on GS: buy Feb 6, 2026 put spread using the 850 strike and the nearest liquid lower strike (e.g., 850/700), size to cap max loss to the premium paid; close or roll if implied vol increases >50% or GS moves >15%.
• Pair-trade: for 1% NAV, go long the QGEN call spread above and short 1% NAV of XLF (or 0.5% GS equity) to neutralize macro beta; reassess at 30 days before QGEN expiry and unwind if spread P&L hits ±25%.
• If implied volatility on QGEN rises >40% from today or open interest fails to increase alongside volume, consider selling a 30–60 day calendar spread (sell short-dated calls, buy May calls) sized at 0.5% NAV—capture mean reversion of dealer hedging flows.